Lapatinib (GW-572016) Ditosylate

Catalog No.S1028

Lapatinib (GW-572016) Ditosylate Chemical Structure

Molecular Weight(MW): 925.46

Lapatinib (GW-572016) Ditosylate is a potent EGFR and ErbB2 inhibitor with IC50 of 10.8 and 9.2 nM in cell-free assays, respectively.

Size Price Stock Quantity  
In DMSO USD 191 In stock
USD 147 In stock
USD 400 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 54 Publications

7 Customer Reviews

  • Combination of NVP-AEW541 and lapatinib cooperatively inhibits the growth of NVP-AEW541 resistant murine rhabdomyosarcoma primary cell cultures with Igf1r/Her2 complexes. Cell viability assay for Naïve, untreated (U20325; A) and NVP-AEW541 innately resistant mouse rhabdomyosarcoma primary culture (U44676; B) treated with varying concentrations of NVP-AEW541, lapatinib, or a combination of both. Naïve cells (U20325) were sensitive to NVP-AEW541, but lapatinib had no cooperativity. In contrast, NVP-AEW541 at moderate doses increased cell growth in resistant cell cultures (U44676). However, this paradoxical effect was reduced by the addition of lapatinib, although lapatinib treatment alone had very little effect. C, the NVP-AEW541 resistant primary tumor cell line (U44676) was treated with DMSO, 5 μmol/L lapatinib, 5 μmol/L NVP-AEW541, and a combination of 5 μmol/L NVP-AEW541+lapatinib for 25 minutes and Western blot analysis was done on lysates for p-Igf1r and p-Her2.

    Mol Cancer Ther 2011 10:697-707. Lapatinib (GW-572016) Ditosylate purchased from Selleck.

    (B-C) LNCaP (B) and LNCaP-AI (C) cells were transiently transfected with sPLA2-IIa(-800)-Luc (0.5 lg). The cells were then treated with Erlotinib (20 μM), Gefitinib (20 μM), Lapatinib (20 μM), CI-1033 (8 μM), LY294002 (20 μM) and Bortezomib (20 μM) without or with EGF (100 ng/ml) for 24 h. Luciferase assay was performed according to a standard protocol with Renilla luciferase as an internal control. Data are presented as the mean (±SD) of duplicate values of a representative experiment that was independently repeated for five times.

    Carcinogenesis 2010 31, 1948–1955 . Lapatinib (GW-572016) Ditosylate purchased from Selleck.

  • LNCaP-AI cells were starved in 1% stripped medium for 24 h. The cells were then treated with Erlotinib (20 μM), Gefitinib (20 μM), Lapatinib (20 μM), CI-1033 (8 μM), LY294002 (20 μM) and Bortezomib (20 μM) for 24 h. Cell culture medium was collected from each sample and subjected to ELISA for sPLA2-IIa. The condition medium samples were diluted 10 times for ELISA. Average of duplicate samples was converted to nanogram per milliliter against standard curve. The data represent one of five repeated experiments.

     

     

    Carcinogenesis 2010 31, 1948–1955. Lapatinib (GW-572016) Ditosylate purchased from Selleck.

    Impact of the TKI erlotinib, lapatinib, dasatinib, and sorafenib on the viability of MDS/AML cells. MOLM-13 (A) and HL-60 (B) cells were incubated with the indicated doses (given in mM below the x-axis) of the 4 TKI, and cellular viability was assessed by MTT assay after 24, 48 and 72 h of incubation. Changes in viability are given as percentage of cells as compared to non-treated control samples. This experiment was repeated at least three times, yielding comparable results. Graphs show representative results of one experiment carried out in duplicates (mean   standard deviation).

     

     

    Biochem Pharmacol 2011 82, 1457-1466. Lapatinib (GW-572016) Ditosylate purchased from Selleck.

  • Capacity of the TKI to overcome the AML-typical differentiation blockage. The myeloid cell lines MOLM-13 and HL-60 were incubated for 6 days with 0.01% DMSO (serving as a negative solvent control), 1 μM of ATRA (serving as a positive control), as well as with the indicated doses of the four TKI. (A) Representative May-Gruenwald-Giemsa staining of MOLM-13 cells, (B) quantitation of the percentage of MOLM-13 cells exhibiting at least two morphological signs of differentiation (that is a decrease in cytoplasmic basophilia, a reduction of the nucleo-cytoplasmic ratio, appearance of nuclear lobulation and/or cytoplasmic granules). Percentages were evaluated by examining at least 100 cells/condition; (C) representative FACS overlays of MOLM-13 cells depicting TKI-induced CD11b expression (black line) as compared to the isotype (shaded grey); (D) quantitation of TKI-induced CD11b-expression in MOLM-13 cells; (E) representative slides depicting morphology/staining of MOLM-13 cells assessed in the NBT-reduction assay; (F) respective quantitative assessment demonstrating the NBT-reducing capacity under the different drugs; (G) representative May-Gruenwald-Giemsa staining of HL-60 cells.

     

     

    Biochem Pharmacol 2011 82, 1457-1466. Lapatinib (GW-572016) Ditosylate purchased from Selleck.

    Inhibition of signaling pathway activation in lung tumor cell lines by kinase inhibitors. Lung tumor cells were cultured in 10% FBS until reaching ∼80% confluence and then the cells were starved in serum-free medium for overnight, followed by 4-hour treatment with the inhibitors. Cell lysates were then prepared and used for determination of the pathway activation signals by the CEER assay.

    Int J Proteomics 2011 2011, 215496. Lapatinib (GW-572016) Ditosylate purchased from Selleck.

  • After starved in serum-free medium for 24h,T47D cells incubated with the indicated concentrations of Lapatinib for 3h,followed by 20-minute  stimolation of 100ng/ml EGF.

     

     

    Dr. Zhang of Tianjin Medical University. Lapatinib (GW-572016) Ditosylate purchased from Selleck.

Purity & Quality Control

Choose Selective HER2 Inhibitors

Biological Activity

Description Lapatinib (GW-572016) Ditosylate is a potent EGFR and ErbB2 inhibitor with IC50 of 10.8 and 9.2 nM in cell-free assays, respectively.
Targets
ErbB2 [1]
(Cell-free assay)
EGFR [1]
(Cell-free assay)
ErbB4 [1]
(Cell-free assay)
9.2 nM 10.8 nM 367 nM
In vitro

Lapatinib Ditosylate weakly inhibits the activity of ErbB4 with IC50 of 367 nM, and displays >300-fold selectivity for EGFR and ErbB2 over other kinases such as c-Src, c-Raf, MEK, ERK, c-Fms, CDK1, CDK2, p38, Tie-2, and VEGFR2. Lapatinib Ditosylate significantly inhibits receptor autophosphorylation of EGFR and ErbB2 in a dose-dependent manner with IC50 of 170 nM and 80 nM, respectively in HN5 cells; as well as 210 nM and 60 nM, respectively in BT474 cells. Unlike OSI-774 and Iressa (ZD1839) which preferentially inhibit the growth of the EGFR-overexpressing cells, Lapatinib Ditosylate inhibits the growth of both EGFR- and ErbB2-overexpressing cells. Lapatinib Ditosylate displays higher inhibitory activity against EGFR- or ErbB2-overexpressing cells with IC50 of 0.09-0.21 μM, compared with cells expressing low levels of EGFR or ErbB2 with IC50 of 3-12 μM, and exhibits ~100-fold selectivity over the normal fibroblast cells. Lapatinib Ditosylate potently inhibits the outgrowth of EGFR-overexpressing HN5 and A-431 cells, as well as ErbB2-overexpressing BT474 and N87 cells, and significantly induces G1 arrest of HN5 cells and apoptosis of BT474 cells, which are associated with inhibition of AKT phosphorylation. [1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HN5 cell line M{Dle3Bzd2yrZnXyZZRqd25iYYPzZZk> NYLnWWFRSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIUlUh[2WubDDsbY5mNCCLQ{WwQVAvODJ3IN88US=> MYmxOlQ5Ozd5Mh?=
BT474 cell line MUXQdo9tcW[ncnH0bY9vKGG|c3H5 MUPBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEKWNEe0JINmdGxibHnu[UwhUUN3ME2wMlAzPSEQvF2= MWSxOlQ5Ozd5Mh?=
HN5 cell MnzuS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MXHJcohq[mm2aX;uJI9nKEiQNTDj[YxtKGe{b4f0bEBi\nSncjC3NkBpenNuIFnDOVA:OC5zMjFOwG0> MX6xOlc4PzRzMB?=
BT474 cell MX7Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MYnJcohq[mm2aX;uJI9nKEKWNEe0JINmdGxiZ4Lve5RpKGGodHXyJFczKGi{czygTWM2OD1yLkC4JO69VQ>? MWexOlc4PzRzMB?=
N87 cell M{D5TGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NUHxUVhMUW6qaXLpeIlwdiCxZjDOPFch[2WubDDndo94fGhiYX\0[ZIhPzJiaILzMEBKSzVyPUCuNFgh|ryP MVOxOlc4PzRzMB?=
HFF cell NHTNVm9Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= MXzJcohq[mm2aX;uJI9nKEiIRjDj[YxtKGe{b4f0bEwhUUN3ME25Mlkh|ryP NUTRZ45QOTZ5N{e0NVA>
SKBR3 cells MVTDfZRwfG:6aXPpeJkh[XO|YYm= MoDtR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gV2tDWjNiY3XscJMh[W[2ZYKgO|IhcHK|IHL5JHNTSiCjc4PhfUwhUUN3ME2wMlAyPyEQvF2= NWPZUVZ{OTlyMki0NlU>
A431 cells NEDRS4lEgXSxdH;4bYNqfHliYYPzZZk> MUfDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDBOFMyKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDTVmIh[XO|YYmsJGlEPTB;MD6xNFQh|ryP M37wbVE6QDh6N{[x
SKBR3 cells MXnDfZRwfG:6aXPpeJkh[XO|YYm= NXmzcHBWS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hW0uEUkOgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KFOUQjDhd5NigSxiSVO1NF0xNjB{OTFOwG0> NGH1fHUyQTh6OEe2NS=>
HepG2 cells NGH3[GNRem:uaX\ldoF1cW:wIHHzd4F6 NUfqc2IzSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDI[ZBIOiClZXzsd{Bi\nSncjDodpMh[nliQWTQJINwdnSnboSgZZN{[XluIFnDOVA:Pi5{NzFOwG0> NE\iZ2QzODF2M{e3PC=>
Hep3B2 cells MmLlVJJwdGmoZYLheIlwdiCjc4PhfS=> M3ezeWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSHXwN2IzKGOnbHzzJIFnfGW{IHjyd{BjgSCDVGCgZ49vfGWwdDDhd5NigSxiSVO1NF02NjR7IN88US=> NFHLXlIzODF2M{e3PC=>
SKHEP1 cells MV3Qdo9tcW[ncnH0bY9vKGG|c3H5 M1XxTWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iU1vISXAyKGOnbHzzJIFnfGW{IHjyd{BjgSCDVGCgZ49vfGWwdDDhd5NigSxiSVO1NF02NjNizszN MWKyNFE1Ozd5OB?=
MCF7 cells MYjQdo9tcW[ncnH0bY9vKGG|c3H5 NHTvN25CdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3DSlch[2WubIOgZYZ1\XJiaILzJIJ6KEGWUDDjc451\W62IHHzd4F6NCCLQ{WwQVYvPiEQvF2= MWqyNFE1Ozd5OB?=
MDA-MB-231 cells NEfoOlFRem:uaX\ldoF1cW:wIHHzd4F6 MkLMRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCPRFGtUWIuOjNzIHPlcIx{KGGodHXyJIhzeyCkeTDBWHAh[2:wdHXueEBie3OjeTygTWM2OD13LkSg{txO M{nucVIxOTR|N{e4
SK-BR-3 cells NV\0enRrWHKxbHnm[ZJifGmxbjDhd5NigQ>? MlruRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCVSz3CVk0{KGOnbHzzJIFnfGW{IHjyd{BjgSCDVGCgZ49vfGWwdDDhd5NigSxiSVO1NF0xNjB2IN88US=> NYC1Z2g5OjBzNEO3O|g>
A431 cells M2m0NmZ2dmO2aX;uJIF{e2G7 MWHJcohq[mm2aX;uJI9nKEWJRmKgbY51emGlZXzseYxieiCyaH;zdIhwenmuYYTpc44hcW5iaIXtZY4hSTR|MTDj[YxteyCkeTDFUGlUSSxiSVO1NF0xNjB3MjFOwG0> MnX0NlA{PDZ4NUW=
N87 cells NHzkTWNHfW6ldHnvckBie3OjeR?= NGnzT5hKdmirYnn0bY9vKG:oIFXyZmIzKGmwdILhZ4VtdHWuYYKgdIhwe3Cqb4L5cIF1cW:wIHnuJIh2dWGwIF64O{Bk\WyuczDifUBGVEmVQTygTWM2OD1yLkGg{txO M4DJd|IxOzR4NkW1
MIAPaCa cells NFf1W25HfW6ldHnvckBie3OjeR?= MoTVTY5pcWKrdHnvckBw\iCHR1\SJJBpd3OyaH;yfYxifGmxbjDpckBpfW2jbjDNTWFR[UOjIHPlcIx{KGK7IFXMTXNCNCCLQ{WwQVAvPDN|IN88US=> NWHZOVZsOjB6MUe1NlM>
MIAPaCa cells M4W0VmZ2dmO2aX;uJIF{e2G7 MV\Jcohq[mm2aX;uJI9nKEWUQnKyJJBpd3OyaH;yfYxifGmxbjDpckBpfW2jbjDNTWFR[UOjIHPlcIx{KGK7IFXMTXNCNCCLQ{WwQVAvOTRizszN M4[ycFIxQDF5NUKz
CAL27 cells M1;zT2N6fG:2b4jpZ4l1gSCjc4PhfS=> MkjjR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gR2FNOjdiY3XscJMhd3[ncnX4dJJme3OrbnegSWdHWiCkeTDy[ZNignW{aX6g[JlmKHKnZIXjeIlwdiCjc4PhfUwhUUN3ME2wMlAxPyEQvF2u Mmn4NlExQDB4Mkm=
SKOV3 cells M{C3e2N6fG:2b4jpZ4l1gSCjc4PhfS=> NFL6WJhEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBUU0:YMzDj[YxteyCxdnXy[ZhxemW|c3nu[{BJTVJ{IHL5JJJme2G8dYLpckBlgWVicnXkeYN1cW:wIHHzd4F6NCCLQ{WwQVAvODB|IN88UU4> NEfKUYszOTB6ME[yPS=>
CAL27 cells NHfZXVhHfW6ldHnvckBie3OjeR?= NWLJfW1FOTZiaB?= MoHqTY5pcWKrdHnvckBw\iCHR1[tbY5lfWOnZDDFS2ZTKHCqb4PwbI9zgWyjdHnvckBqdiCqdX3hckBESUx{NzDj[YxteyCxdnXy[ZhxemW|c3nu[{BGT0[UIHHmeIVzKDF4IHjyd{BjgSCZZYP0[ZJvKGKub4SsJGlEPTB;MD6wN|Ih|ryP MUmyNVA5ODZ{OR?=
SK-BR-3 cells MUTQdo9tcW[ncnH0bY9vKGG|c3H5 M4PJU2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgSZJjSjJib4\ldoV5eHKnc4PpcochcHWvYX6gV2suSlJvMzDj[YxteyCkeTDNWHQh[XO|YYmsJGlEPTB;MD6wN|Ih|ryP M17RcVIyPTdyOESz
BXF T24 cells M{C1U2N6fG:2b4jpZ4l1gSCjc4PhfS=> NXzDVpB2PCCmYYnz M1P6c2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGJZTiCWMkSgZ4VtdHNiYX\0[ZIhPCCmYYnzJIJ6KHC{b4Dp[Il2dSCrb3Tp[IUhe3SjaX7pcocu[mG|ZXSg[ox2d3KxbXX0dolkKGGwYXz5d4l{NCCLQ{WwQVkvPjVizszN NWLtXI1ROjJzNkm2NFE>
CXF 269L cells MoTKR5l1d3SxeHnjbZR6KGG|c3H5 MUm0JIRigXN? MmnzR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gR3hHKDJ4OVygZ4VtdHNiYX\0[ZIhPCCmYYnzJIJ6KHC{b4Dp[Il2dSCrb3Tp[IUhe3SjaX7pcocu[mG|ZXSg[ox2d3KxbXX0dolkKGGwYXz5d4l{NCCLQ{WwQVgvOzZizszN Ml74NlIyPjl4MEG=
DIFI cells MnL6R5l1d3SxeHnjbZR6KGG|c3H5 NXTvNlV{PCCmYYnz NU\LbXBqS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hTEmISTDj[YxteyCjZoTldkA1KGSjeYOgZpkheHKxcHnkbZVuKGmxZHnk[UB{fGGrbnnu[{1j[XOnZDDmcJVwem:vZYTybYMh[W6jbInzbZMtKEmFNUC9NE4zOzVizszN MoPGNlIyPjl4MEG=
HT-29 cells MUPDfZRwfG:6aXPpeJkh[XO|YYm= M{jNbVQh\GG7cx?= MWHDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDIWE0zQSClZXzsd{Bi\nSncjC0JIRigXNiYomgdJJweGmmaYXtJIlw\GmmZTDzeIFqdmmwZz3iZZNm\CCobIXvdo9u\XS{aXOgZY5idHm|aYOsJGlEPTB;ND62NkDPxE1? NGXGVIwzOjF4OU[wNS=>
RKO cells MVzDfZRwfG:6aXPpeJkh[XO|YYm= MofZOEBl[Xm| NX;hXlZ[S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hWkuRIHPlcIx{KGGodHXyJFQh\GG7czDifUBxem:yaXTpeY0hcW:maXTlJJN1[WmwaX7nMYJie2WmIH\seY9zd22ndILpZ{BidmGueYPpd{whUUN3ME21MlM2KM7:TR?= NIDzdoYzOjF4OU[wNS=>
GXF251L cells NGTr[HpEgXSxdH;4bYNqfHliYYPzZZk> NXXYN|BSPCCmYYnz NFnjZZZEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBIYEZ{NUHMJINmdGy|IHHmeIVzKDRiZHH5d{BjgSCycn;wbYRqfW1iaX;kbYRmKHO2YXnubY5oNWKjc3XkJIZtfW:{b33leJJq[yCjbnHsfZNqeyxiSVO1NF0yNjR6IN88US=> NFjUeWgzOjF4OU[wNS=>
LIXF 575L cells MoPpR5l1d3SxeHnjbZR6KGG|c3H5 NUjKVVVHPCCmYYnz MUjDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDMTXhHKDV5NVygZ4VtdHNiYX\0[ZIhPCCmYYnzJIJ6KHC{b4Dp[Il2dSCrb3Tp[IUhe3SjaX7pcocu[mG|ZXSg[ox2d3KxbXX0dolkKGGwYXz5d4l{NCCLQ{WwQVcvOThizszN NEHGWoczOjF4OU[wNS=>
LXFA 289L cells M1L2ZWN6fG:2b4jpZ4l1gSCjc4PhfS=> NF\3fo81KGSjeYO= M36wcmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGxZTkFiMki5UEBk\WyuczDh[pRmeiB2IHThfZMh[nlicILvdIllcXWvIHnv[Ill\SC|dHHpcolv\y2kYYPl[EBndHWxcn;t[ZRzcWNiYX7hcJl{cXNuIFnDOVA:PS55OTFOwG0> M{HhSFIzOTZ7NkCx
LXFA 526L M3\NO2N6fG:2b4jpZ4l1gSCjc4PhfS=> MnvoOEBl[Xm| M3f6TmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGxZTkFiNUK2UEBk\WyuczDh[pRmeiB2IHThfZMh[nlicILvdIllcXWvIHnv[Ill\SC|dHHpcolv\y2kYYPl[EBndHWxcn;t[ZRzcWNiYX7hcJl{cXNuIFnDOVA:PC5{MTFOwG0> MUGyNlE3QTZyMR?=
LXFA 629L cells MX3DfZRwfG:6aXPpeJkh[XO|YYm= NID1Zno1KGSjeYO= MWLDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDMXGZCKDZ{OVygZ4VtdHNiYX\0[ZIhPCCmYYnzJIJ6KHC{b4Dp[Il2dSCrb3Tp[IUhe3SjaX7pcocu[mG|ZXSg[ox2d3KxbXX0dolkKGGwYXz5d4l{NCCLQ{WwQVIvQDdizszN Mo\uNlIyPjl4MEG=
LXFL 1121L cells MXfDfZRwfG:6aXPpeJkh[XO|YYm= NHi1SlM1KGSjeYO= MW\DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDMXGZNKDFzMkHMJINmdGy|IHHmeIVzKDRiZHH5d{BjgSCycn;wbYRqfW1iaX;kbYRmKHO2YXnubY5oNWKjc3XkJIZtfW:{b33leJJq[yCjbnHsfZNqeyxiSVO1NF04Njd|IN88US=> NHLQTFgzOjF4OU[wNS=>
LXFL 529L cells NV;tOJBXS3m2b4TvfIlkcXS7IHHzd4F6 Mn;COEBl[Xm| NFzUUYpEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBNYE[OIEWyPWwh[2WubIOgZYZ1\XJiNDDkZZl{KGK7IIDyc5Bq\Gm3bTDpc4Rq\GVic4ThbY5qdmdvYnHz[YQh\my3b4LvcYV1emmlIHHuZYx6e2m|LDDJR|UxRTNwNUGg{txO NVvWOoxsOjJzNkm2NFE>
MCF7 cells MX7DfZRwfG:6aXPpeJkh[XO|YYm= NWHVWIU{PCCmYYnz MmfMR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUWNHPyClZXzsd{Bi\nSncjC0JIRigXNiYomgdJJweGmmaYXtJIlw\GmmZTDzeIFqdmmwZz3iZZNm\CCobIXvdo9u\XS{aXOgZY5idHm|aYOsJGlEPTB;ND64N{DPxE1? NYrrZpI3OjJzNkm2NFE>
MDA231 cells M2TqSWN6fG:2b4jpZ4l1gSCjc4PhfS=> NUTPTm4zPCCmYYnz M1TCcmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1FSTJ|MTDj[YxteyCjZoTldkA1KGSjeYOgZpkheHKxcHnkbZVuKGmxZHnk[UB{fGGrbnnu[{1j[XOnZDDmcJVwem:vZYTybYMh[W6jbInzbZMtKEmFNUC9O{44KM7:TR?= NVP2XIx1OjJzNkm2NFE>
OVXF 899L MUHDfZRwfG:6aXPpeJkh[XO|YYm= NWjkd3FQPCCmYYnz NEPWOpFEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBQXliIIEi5PWwh[2WubIOgZYZ1\XJiNDDkZZl{KGK7IIDyc5Bq\Gm3bTDpc4Rq\GVic4ThbY5qdmdvYnHz[YQh\my3b4LvcYV1emmlIHHuZYx6e2m|LDDJR|UxRTNwM{Wg{txO MUOyNlE3QTZyMR?=
PAXF 546L cells NY\ybYRoS3m2b4TvfIlkcXS7IHHzd4F6 MUC0JIRigXN? NGrBdXBEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBRSViIIEW0Omwh[2WubIOgZYZ1\XJiNDDkZZl{KGK7IIDyc5Bq\Gm3bTDpc4Rq\GVic4ThbY5qdmdvYnHz[YQh\my3b4LvcYV1emmlIHHuZYx6e2m|LDDJR|UxRTZwMUKg{txO Mo\QNlIyPjl4MEG=
PANC1 cells MlfRR5l1d3SxeHnjbZR6KGG|c3H5 NYjlbZNIPCCmYYnz M3TqU2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHBCVkNzIHPlcIx{KGGodHXyJFQh\GG7czDifUBxem:yaXTpeY0hcW:maXTlJJN1[WmwaX7nMYJie2WmIH\seY9zd22ndILpZ{BidmGueYPpd{whUUN3ME24MlEzKM7:TR?= NWfoWJh7OjJzNkm2NFE>
22Rv1 cell NYHVcGtMS3m2b4TvfIlkcXS7IHHzd4F6 MVu0JIRigXN? NHu3eIJEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckAzOlK4MTDj[YxteyCjZoTldkA1KGSjeYOgZpkheHKxcHnkbZVuKGmxZHnk[UB{fGGrbnnu[{1j[XOnZDDmcJVwem:vZYTybYMh[W6jbInzbZMtKEmFNUC9Ok4xPiEQvF2= Mo\lNlIyPjl4MEG=
DU145 cells MWLDfZRwfG:6aXPpeJkh[XO|YYm= M3rueVQh\GG7cx?= MVzDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDEWVE1PSClZXzsd{Bi\nSncjC0JIRigXNiYomgdJJweGmmaYXtJIlw\GmmZTDzeIFqdmmwZz3iZZNm\CCobIXvdo9u\XS{aXOgZY5idHm|aYOsJGlEPTB;Mj65PUDPxE1? NV;3[nRkOjJzNkm2NFE>
LNCAP cells MXLDfZRwfG:6aXPpeJkh[XO|YYm= M{Cx[lQh\GG7cx?= MUPDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDMUmNCWCClZXzsd{Bi\nSncjC0JIRigXNiYomgdJJweGmmaYXtJIlw\GmmZTDzeIFqdmmwZz3iZZNm\CCobIXvdo9u\XS{aXOgZY5idHm|aYOsJGlEPTB;Mz62PEDPxE1? NYfYcXNzOjJzNkm2NFE>
PC3M cells NGnoV|NEgXSxdH;4bYNqfHliYYPzZZk> MWG0JIRigXN? MWfDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDQR|NOKGOnbHzzJIFnfGW{IESg[IF6eyCkeTDwdo9xcWSrdX2gbY9lcWSnIIP0ZYlvcW6pLXLhd4VlKG[udX;yc41mfHKrYzDhcoFtgXOrczygTWM2OD12LkW1JO69VQ>? MXGyNlE3QTZyMR?=
NIH/3T3 cells M1zSPHBzd2yrZnXyZZRqd25iYYPzZZk> MYS3NkBp NVjHOGh1SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBud3W|ZTDOTWgwO1R|IHPlcIx{KGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUC9OE4{KM7:TR?= M{fOZVIzPTl3MUe3
NCI-H1648 cell MXXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NGLU[lJKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3INVY1QCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTBwMEK1OFQh|ryP NH:1OmNUSU6JRWK=
NMC-G1 cell MV;Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MlvKTY5pcWKrdHnvckBw\iCqdX3hckBPVUNvR{GgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zMlU1PTBzIN88US=> MlvMV2FPT0WU
NTERA-S-cl-D1 cell NV;D[oZ7T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NV;BZ4RUUW6qaXLpeIlwdiCxZjDoeY1idiCQVFXSRU1UNWOuLVSxJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Ok4zPjV4MTFOwG0> MXTTRW5ITVJ?
OCUB-M cell NWLUXmJTT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MmrGTY5pcWKrdHnvckBw\iCqdX3hckBQS1WELV2gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlA2PzRizszN MkHOV2FPT0WU
OS-RC-2 cell MlHPS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MnHjTY5pcWKrdHnvckBw\iCqdX3hckBQWy2UQz2yJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU46QTF7OTFOwG0> MVnTRW5ITVJ?
OVCAR-4 cell M1LHdWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M37QTmlvcGmkaYTpc44hd2ZiaIXtZY4hV1[FQWKtOEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVkvOTF4N{Wg{txO MkfZV2FPT0WU
RL95-2 cell NYDsW4N1T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NV3ZZYI{UW6qaXLpeIlwdiCxZjDoeY1idiCUTEm1MVIh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0{NjF3Nkeg{txO MlrYV2FPT0WU
SW954 cell M1v0Wmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NV3W[4RxUW6qaXLpeIlwdiCxZjDoeY1idiCVV{m1OEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUvOzl{NEWg{txO NY\uS|dUW0GQR1XS
SW962 cell M{Xuemdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NFnSZXNKdmirYnn0bY9vKG:oIHj1cYFvKFOZOU[yJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OU4{QTJ2NTFOwG0> M1fESHNCVkeHUh?=
TE-1 cell MYrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NV3lNIxyUW6qaXLpeIlwdiCxZjDoeY1idiCWRT2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OU4xOjF3OTFOwG0> NI\n[|dUSU6JRWK=
A253 cell NHP3U|BIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NGTH[2dKdmirYnn0bY9vKG:oIHj1cYFvKEF{NUOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yMlA1QDNizszN NVXiOppsW0GQR1XS
A388 cell NEGwZlFIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NXXLSYdrUW6qaXLpeIlwdiCxZjDoeY1idiCDM{i4JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Nk4xPDh|IN88US=> MWLTRW5ITVJ?
BB30-HNC cell MluxS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MYfJcohq[mm2aX;uJI9nKGi3bXHuJGJDOzBvSF7DJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU46PzN|NTFOwG0> M37CVXNCVkeHUh?=
TE-12 cell MorTS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NWLFW5J4UW6qaXLpeIlwdiCxZjDoeY1idiCWRT2xNkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvPzJ{NUig{txO MoDqV2FPT0WU
TE-5 cell M133fGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M1njR2lvcGmkaYTpc44hd2ZiaIXtZY4hXEVvNTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuNlQ3PTRizszN MXHTRW5ITVJ?
TE-6 cell NXTtZXVQT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= Mn7FTY5pcWKrdHnvckBw\iCqdX3hckBVTS14IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD60PVA2PyEQvF2= M3nzR3NCVkeHUh?=
TE-8 cell M4LGN2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M1rTUWlvcGmkaYTpc44hd2ZiaIXtZY4hXEVvODDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUSuNFM4OyEQvF2= NUfYZ3g2W0GQR1XS
TE-9 cell MU\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M3fUZmlvcGmkaYTpc44hd2ZiaIXtZY4hXEVvOTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGuOVUzODFizszN NUTKWJF1W0GQR1XS
TK10 cell NIrDUpdIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MVHJcohq[mm2aX;uJI9nKGi3bXHuJHRMOTBiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD12LkG2OVIzKM7:TR?= NWPENJBqW0GQR1XS
DSH1 cell NHP4b29Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= NFXuT2NKdmirYnn0bY9vKG:oIHj1cYFvKESVSEGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlA6Ozl4IN88US=> NFfpR3JUSU6JRWK=
ECC12 cell M2\3bGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MWnJcohq[mm2aX;uJI9nKGi3bXHuJGVESzF{IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD6wPVI{OSEQvF2= M4Tn[XNCVkeHUh?=
EKVX cell NWTT[Xc3T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NWHGR3E5UW6qaXLpeIlwdiCxZjDoeY1idiCHS2\YJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE41PDh5NDFOwG0> M1HoenNCVkeHUh?=
HCC2218 cell NVL6cW1VT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M2PLTWlvcGmkaYTpc44hd2ZiaIXtZY4hUEOFMkKxPEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvODV|Mk[g{txO NFXwb|JUSU6JRWK=
LB2241-RCC cell NVe1OXdKT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NHjSd2lKdmirYnn0bY9vKG:oIHj1cYFvKEyEMkK0NU1TS0NiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zLkG1OFA{KM7:TR?= M{fmXHNCVkeHUh?=
LB996-RCC cell NVexU2pKT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NFPqd|lKdmirYnn0bY9vKG:oIHj1cYFvKEyEOUm2MXJESyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTFwM{[yNlgh|ryP NGf3V3FUSU6JRWK=
LC-1F cell NIHYOmhIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NVfwdpVLUW6qaXLpeIlwdiCxZjDoeY1idiCOQz2xSkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvOzh{NESg{txO M4DjS3NCVkeHUh?=
LS-513 cell M1\tZWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NI\KW3lKdmirYnn0bY9vKG:oIHj1cYFvKEyVLUWxN{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVMvPDByNEGg{txO M4G2[3NCVkeHUh?=

... Click to View More Cell Line Experimental Data

In vivo Oral administration of Lapatinib Ditosylate (~100 mg/kg) twice daily significantly inhibits the growth of BT474 and HN5 xenografts in a dose-dependent manner. [1]

Protocol

Kinase Assay:[1]
+ Expand

In vitro kinase assays:

The IC50 values for inhibition of enzyme activity are generated by measuring inhibition of phosphorylation of a peptide substrate. The intracellular kinase domains of EGFR and ErbB2 are purified from a baculovirus expression system. EGFR and ErbB2 reactions are performed in 96-well polystyrene round-bottomed plates in a final volume of 45 μL. Reaction mixtures contain 50 mM 4-morpholinepropanesulfonic acid (pH 7.5), 2 mM MnCl2, 10 μM ATP, 1 μCi of [γ33P] ATP/reaction, 50 μM Peptide A [Biotin-(amino hexonoic acid)-EEEEYFELVAKKK-CONH2], 1 mM dithiothreitol, and 1 μL of DMSO containing serial dilutions of Lapatinib beginning at 10 μM. The reaction is initiated by adding the indicated purified type-1 receptor intracellular domain. The amount of enzyme added is 1 pmol/reaction (20 nM). Reactions are terminated after 10 minutes at 23°C by adding 45 μL of 0.5% phosphoric acid in water. The terminated reaction mix (75 μL) is transferred to phosphocellulose filter plates. The plates are filtered and washed three times with 200 μL of 0.5% phosphoric acid. Scintillation cocktail (50 μL) is added to each well, and the assay is quantified by counting in a Packard Topcount. IC50 values are generated from 10-point dose-response curves.
Cell Research:[1]
+ Expand
  • Cell lines: HFF, MCF-7, T47D, A-431, HN5, BT474, N87, CaLu-3, HB4a, and HB4a c5.2
  • Concentrations: Dissolved in DMSO, final concentrations ~100 μM
  • Incubation Time: 72 hours
  • Method: Cells are exposed to various concentrations of Lapatinib for 72 hours. Relative cell number is estimated using methylene blue staining. The absorbance at 620 nm is read in a Spectra microplate reader. Cell death and cell cycle analysis are assessed by propidium iodide staining and antibody detection of incorporated BrdUrd and staining with propidium iodide.
    (Only for Reference)
Animal Research:[1]
+ Expand
  • Animal Models: CD-1 nude female mice implanted s.c. with HN5 cells, and C.B-17 SCID female mice implanted s.c. with BT474 cells
  • Formulation: Formulated in a vehicle of sulfo-butyl-ether-β-cyclodextrin 10% aqueous solution (CD10)
  • Dosages: ~100 mg/kg
  • Administration: Orally twice daily
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (108.05 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+30% PEG 300+ddH2O
For best results, use promptly after mixing.
10mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 925.46
Formula

C29H26ClFN4O4S.2C7H8O3S

CAS No. 388082-77-7
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03784014 Not yet recruiting Soft Tissue Sarcoma Institut National de la Santé Et de la Recherche Médicale France|Commissariat A L''energie Atomique|Institut Bergonié|Plateforme labellisée Inca – Institut Bergonié Bordeaux|Plateforme labellisée Inca – Hôpital Européen Georges Pompidou Paris|CIC-EC 1401/EUCLID March 2019 Phase 3
NCT03784014 Not yet recruiting Soft Tissue Sarcoma Institut National de la Santé Et de la Recherche Médicale France|Commissariat A L''energie Atomique|Institut Bergonié|Plateforme labellisée Inca – Institut Bergonié Bordeaux|Plateforme labellisée Inca – Hôpital Européen Georges Pompidou Paris|CIC-EC 1401/EUCLID March 2019 Phase 3
NCT03523585 Recruiting Breast Cancer Daiichi Sankyo Inc.|Daiichi Sankyo Co. Ltd. August 1 2018 Phase 3
NCT03523585 Recruiting Breast Cancer Daiichi Sankyo Inc.|Daiichi Sankyo Co. Ltd. August 1 2018 Phase 3
NCT03500380 Recruiting Breast Neoplasms|Breast Diseases|Capecitabine|HER2-positive Breast Cancer|HER2 Positive Breast Carcinoma RemeGen April 2018 Phase 2
NCT03500380 Recruiting Breast Neoplasms|Breast Diseases|Capecitabine|HER2-positive Breast Cancer|HER2 Positive Breast Carcinoma RemeGen April 2018 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    If I need to use S1028 for treating tumor-bearing mice with injection, how could I prepare the solution?

  • Answer:

    S1028 Lapatinib Ditosylate can be dissolved in 2% DMSO/30% PEG 300/ddH2O at 10 mg/ml as clear solution.

HER2 Signaling Pathway Map

HER2 Inhibitors with Unique Features

Related HER2 Products4

Tags: buy Lapatinib (GW-572016) Ditosylate | Lapatinib (GW-572016) Ditosylate supplier | purchase Lapatinib (GW-572016) Ditosylate | Lapatinib (GW-572016) Ditosylate cost | Lapatinib (GW-572016) Ditosylate manufacturer | order Lapatinib (GW-572016) Ditosylate | Lapatinib (GW-572016) Ditosylate distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID